Cytek Biosciences, INC

Cytek Biosciences announced a jury verdict in a patent infringement case, finding in favor on three of four claims but awarding $56 million in damages, which the company plans to challenge.

Cytek Biosciences announced second quarter 2026 financial results, reporting $48.1 million in total revenue, a 6% increase year-over-year, and updated its full-year revenue guidance upwards.

Cytek Biosciences announces departure of Chief Legal Officer and Corporate Secretary, Valerie Barnett, with a severance package and consulting agreement.

Cytek Biosciences, Inc. announced that Chief Legal Officer and Corporate Secretary Valerie Barnett will step down effective June 29, 2026.

Cytek Biosciences announces the resignation of its Senior Vice President, Global Sales and Services, effective June 5, 2026.

Cytek Biosciences reported an 8% increase in Q4 2025 revenue to $62.1 million, its highest quarterly revenue, but full-year revenue grew only 1% to $201.5 million, alongside significant declines in GAAP gross profit and Adjusted EBITDA.

Cytek Biosciences announced a 6% increase in total revenue for both the three and six-month periods ending June 30, 2026, reaching $48.1 million and $92.3 million respectively, though net losses also widened.

Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% year-over-year increase, alongside a net loss of $18.9 million.

Cytek Biosciences reported a net loss of $5.5 million for the third quarter of 2025, driven by increased operating expenses and a decline in product revenue, despite growth in service revenue.

Cytek Biosciences reported a 5% decrease in total revenue and an increased net loss for the first six months of 2025, alongside identified material weaknesses in internal controls.

Cytek Biosciences' Q1 2025 results reveal a revenue decrease, attributed to lower product sales, while the company continues to invest in research and development and commercial infrastructure.

Cytek Biosciences' Q3 2024 results show a slight revenue increase and a return to profitability, balanced against ongoing challenges in product sales and internal control weaknesses.

Cytek Biosciences reported a significant net loss of $66.5 million in 2025, a sharp increase from the previous year, despite minimal 1% revenue growth.

Cytek Biosciences announces a 4% increase in revenue for fiscal year 2024, reaching $200.5 million, while addressing material weaknesses in internal control over financial reporting.

Cytek Biosciences' 2023 annual report reveals a revenue increase but also a net loss and identifies material weaknesses in internal control over financial reporting.

William D. Mccombe, Chief Financial Officer of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.

Glenn P Muir, a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.

Michael Holder, a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.

Richard Chin, a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.

Ming Yan, CHIEF TECHNOLOGY OFFICER and a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.

Ilan Feuchtwang, Chief Legal Officer, Secretary of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 10, 2026.

Cytek Biosciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, detailing director elections, executive compensation, and auditor ratification.

Cytek Biosciences, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cytek Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to elect directors, approve executive compensation, and ratify the selection of its independent accounting firm.

Cytek Biosciences, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cytek Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

A Schedule 13G filing confirms significant beneficial ownership stakes in Cytek Biosciences, Inc. by several entities and an individual.

Boston Partners has disclosed beneficial ownership of 5.9% of Cytek Biosciences, Inc. common stock as of June 30, 2026.

Millennium Management LLC and affiliated entities have reported a 6.1% beneficial ownership stake in Cytek Biosciences, Inc.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 5.2% of Cytek Biosciences, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cytek Biosciences Inc. following an internal realignment.

Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, reported a 5.3% beneficial ownership stake in Cytek Biosciences, Inc.